Vaccination approach to anti-angiogenic treatment of cancer
2015 (English)In: Biochimica et Biophysica Acta. CR. Reviews on Cancer, ISSN 0304-419X, E-ISSN 1879-2561, Vol. 1855, no 2, 155-171 p.Article, review/survey (Refereed) Published
Improvement of patient survival by anti-angiogenic therapy has proven limited. A vaccination approach inducing an immune response against the tumor vasculature combines the benefits of immunotherapy and anti-angiogenesis, and may overcome the limitations of current anti-angiogenic drugs. Strategies to use whole endo: thelial cell vaccines and DNA- or protein vaccines against key players in the VEGF signaling axis, as well as specific markers of tumor endothelial cells, have been tested in preclinical studies. Current clinical trials are now testing the promise of this specific anti-cancer vaccination approach. This review will highlight the state-of-the-art in this exciting field of cancer research.
Place, publisher, year, edition, pages
2015. Vol. 1855, no 2, 155-171 p.
Angiogenesis, Immunology, Tumor vasculature, Vaccination
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy) Cancer and Oncology
IdentifiersURN: urn:nbn:se:uu:diva-257525DOI: 10.1016/j.bbcan.2015.01.005ISI: 000355366400004OAI: oai:DiVA.org:uu-257525DiVA: diva2:839594